Overview

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Status:
RECRUITING
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
adagrasib
cemiplimab
Cetuximab